Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. Amyotrophic lateral sclerosis is an insidiously developing, adult-onset, progressive anterior horn cell degeneration with associated degeneration of descending motor pathways. It has been recognized as an important clinical syndrome since the middle of the 19th century.

  2. 10 kwi 2024 · Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this condition. Coping and support. Learning you have ALS can be devastating. The following tips may help you and your family cope: Take time to grieve.

  3. 10 kwi 2024 · Amyotrophic lateral sclerosis (a-my-o-TROE-fik LAT-ur-ul skluh-ROE-sis), known as ALS, is a nervous system disease that affects nerve cells in the brain and spinal cord. ALS causes loss of muscle control. The disease gets worse over time. ALS is often called Lou Gehrig's disease after the baseball player who was diagnosed with it.

  4. 12 lis 2023 · Amyotrophic lateral sclerosis (ALS) is a deadly CNS neurodegenerative disease. The way ALS is now managed, from diagnosis to prognosis, is still not ideal despite many studies. Early diagnosis can help ALS patients live longer since prompt treatment can halt the disease's development.

  5. 31 maj 2023 · Fasudil, a kinase inhibitor, is currently being tested in a phase II clinical trial for ALS treatment (NCT03792490). As observed in ALS mouse models, it was able to restore the phosphorylation levels of certain proteins associated with synaptic and neuroinflammatory functions [201,202].

  6. 10 kwi 2024 · Mayo Clinic researchers also worked to develop a lab test called a neurofilament light chain test and made it available worldwide. Neurofilament light chain is a marker for several conditions, including ALS. The test can help guide treatment decisions for people who have neurological disorders.

  7. 1 mar 2023 · Overall, all the intraspinal cord transplantation of hNSCs in immunodepressed presymptomatic mice across different treatment regimens (different cell dosages, multiple injection sites) showed a beneficial outcome in slowing the disease onset and progression and prolonging the survival.